Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease

[1]  M. Hayden,et al.  Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. , 2007, Human molecular genetics.

[2]  A. Ogura,et al.  Brain-Derived Neurotrophic Factor Regulates Cholesterol Metabolism for Synapse Development , 2007, The Journal of Neuroscience.

[3]  Vijay H Shah,et al.  Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. , 2006, Human molecular genetics.

[4]  I. Björkhem,et al.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain , 2006, Journal of internal medicine.

[5]  E. Cattaneo,et al.  Cholesterol dysfunction in neurodegenerative diseases: Is Huntington's disease in the list? , 2006, Progress in Neurobiology.

[6]  M. Resh,et al.  Trafficking and signaling by fatty-acylated and prenylated proteins , 2006, Nature chemical biology.

[7]  L. K. Marriott,et al.  Multiple pathways transmit neuroprotective effects of gonadal steroids , 2006, Endocrine.

[8]  P. Calabresi,et al.  Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons , 2006, Neurobiology of Disease.

[9]  Brad E. Pfeiffer,et al.  Brain cholesterol turnover required for geranylgeraniol production and learning in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Elena Cattaneo,et al.  Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.

[11]  J. Olson,et al.  Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease , 2005, The Journal of Neuroscience.

[12]  F. Sundler,et al.  Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease , 2005, The European journal of neuroscience.

[13]  Klaus-Armin Nave,et al.  High cholesterol level is essential for myelin membrane growth , 2005, Nature Neuroscience.

[14]  M. Panas,et al.  Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia , 2005, Annals of neurology.

[15]  S. Pfeffer,et al.  Targeting Rab GTPases to distinct membrane compartments , 2004, Nature Reviews Molecular Cell Biology.

[16]  J. Dietschy,et al.  Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.R400004-JLR200 , 2004, Journal of Lipid Research.

[17]  Thomas Wichmann,et al.  Role of External Pallidal Segment in Primate Parkinsonism: Comparison of the Effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism and Lesions of the External Pallidal Segment , 2004, The Journal of Neuroscience.

[18]  Steve Meaney,et al.  Brain Cholesterol: Long Secret Life Behind a Barrier , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  M. Endres,et al.  HMG‐CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis , 2004, Journal of neurochemistry.

[20]  J. Dietschy,et al.  Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. , 2003, Brain research. Developmental brain research.

[21]  D. Russell,et al.  Knockout of the Cholesterol 24-Hydroxylase Gene in Mice Reveals a Brain-specific Mechanism of Cholesterol Turnover* , 2003, Journal of Biological Chemistry.

[22]  F. Pfrieger,et al.  Cholesterol homeostasis and function in neurons of the central nervous system , 2003, Cellular and Molecular Life Sciences CMLS.

[23]  D. Stein Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? , 2001, Trends in Neurosciences.

[24]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[25]  S. Oliverio,et al.  Early Alterations in Gene Expression and Cell Morphology in a Mouse Model of Huntington's Disease , 2000, Journal of neurochemistry.

[26]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J M Guileyardo,et al.  cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[29]  Nasreen S Jessani,et al.  Characterization of UT2 Cells , 1997, The Journal of Biological Chemistry.

[30]  P. Casey,et al.  Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. , 1996, The Biochemical journal.

[31]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[32]  K. Kristensson,et al.  The lipid compositions of different regions of rat brain during development and aging , 1996, Neurobiology of Aging.

[33]  D. Lütjohann,et al.  Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Morell,et al.  Origin of cholesterol in myelin , 1996, Neurochemical Research.

[35]  T. Chojnacki,et al.  Distribution of Branch Point Prenyltransferases in Regions of Bovine Brain , 1995, Journal of neurochemistry.

[36]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[37]  K. Kristensson,et al.  Rates of cholesterol, ubiquinone, dolichol and dolichyl‐P biosynthesis in rat brain slices , 1990, FEBS letters.

[38]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[39]  L. M. Morales,et al.  Nutritional evaluation of Huntington disease patients. , 1989, The American journal of clinical nutrition.

[40]  H. Kempen,et al.  Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. , 1988, Journal of lipid research.

[41]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[42]  R. Heller,et al.  3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme. , 1984, Journal of lipid research.

[43]  W. Maltese Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease. , 1984, Biochemical medicine.

[44]  J. Mandel,et al.  Total serum cholesterol by isotope dilution/mass spectrometry: a candidate definitive method. , 1980, Clinical chemistry.

[45]  M. Brown,et al.  Active and inactive forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states. , 1979, The Journal of biological chemistry.

[46]  J. Menkes,et al.  Huntington's disease—growth of fibroblast cultures in lipid‐deficient medium: A preliminary report , 1977, Annals of neurology.

[47]  G. Bruyn,et al.  Biochemical studies in Huntington's chorea , 1968, Neurology.

[48]  B. Connors,et al.  Functional Properties of Electrical Synapses between Inhibitory Interneurons of Neocortical Layer 4 , 2022 .

[49]  J. Menkes,et al.  Huntington's disease: growth and fatty acid metabolism of fibroblast cultures in lipid-deficient medium. , 1976, Transactions of the American Neurological Association.